drugset / Trial / NCT02602509

Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers

NCT02602509

Phase 1 Completed 18 enrolled National University Hospital, Singapore
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the bactericidal activity against Mycobacterium tuberculosis of celecoxib in combination with established drugs used to treat tuberculosis (TB). Pharmacokinetics (PK) and whole blood bactericidal activity (WBA) will be measured in healthy volunteers following administration of the study drugs alone and in combination.

Timeline

Start
2015-11
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg
Subject Pyrazinamide Small molecule 25 mg/kg
Subject Rifampin Small molecule 10 mg/kg

Indications